Unnamed Drug Candidate
Oncology
Preclinical/Early ClinicalPipeline Expansion
Key Facts
Indication
Oncology
Phase
Preclinical/Early Clinical
Status
Pipeline Expansion
Company
About Burning Rock Biotech
Burning Rock Biotech's mission is to 'Guard Life via Science' by becoming a new pillar in the international healthcare industry. The company has established itself as a leader in China's precision oncology diagnostics market, with a portfolio of CE-marked kits, a CLIA/CAP-certified lab, and a U.S. FDA Breakthrough Device designation. Its strategy is built on a dual business model of selling IVD products and providing LDT services, while strategically investing in R&D for early cancer detection and a nascent therapeutic pipeline to drive long-term growth.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |